This site is intended for healthcare professionals only

Diabetes Digest


Share this article

Tirzepatide reduces the predicted risk of developing type 2 diabetes

Predicted relative risk of type 2 diabetes reduced by about half at 24 weeks and by about two-thirds at 72 weeks.

In this post hoc analysis of the SURMOUNT-1 trial, the estimated risk of developing type 2 diabetes was compared between treatment with the dual GIP/GLP-1 receptor agonist tirzepatide and placebo.

A total of 2539 people with BMI ≥30 kg/m2 (95% of participants) or BMI ≥27 kg/m2 plus one or more weight-related complication, but without type 2 diabetes, were randomised to tirzepatide (5, 10 or 15 mg) or placebo. The validated Cardiometabolic Disease Staging risk engine was used to estimate the 10-year risk of type 2 diabetes (based on age, sex, race, waist circumference, fasting glucose, blood pressure and lipid levels) at baseline and after 6 and 18 months of treatment.

The estimated 10-year risk of type 2 diabetes was similar between the tirzepatide and placebo groups at baseline, ranging from 22.9% to 24.3%. At 6 months, the risk fell to 11.0–12.5% in the tirzepatide groups (greater reductions seen with higher doses), versus 21.4% in the placebo group. At 18 months, estimated risk had fallen further in the tirzepatide groups, to 9.0–11.4%, compared to 23.0% with placebo. Median relative risk reductions at 18 months were 60.3–69.0% for the tirzepatide groups versus 10.8% for the placebo group.

At baseline, 40% of participants had pre-diabetes. The effect of tirzepatide use was significantly greater in participants with pre-diabetes, with placebo-adjusted risk reductions of 13.4–17.7% at 18 months, than in those with normoglycaemia (placebo-adjusted reductions of 10.7–11.8%). Subgroup analysis according to baseline BMI were consistent with the primary analysis.

The authors conclude that tirzepatide reduced the predicted relative risk of type 2 diabetes by about half at week 24 and by about two-thirds at week 72. The study was limited by the use of 10-year estimations of risk rather than hard outcomes; however, the ongoing SURMOUNT-1 study extension and the SURMOUNT-MMO trial will provide direct evidence on the impact of tirzepatide on progression from pre-diabetes to type 2 diabetes in the future.

Click here to read the study in full.

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.